Analyst Price Target is $19.00
▲ +162.07% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Chimerix in the last 3 months. The average price target is $19.00, with a high forecast of $21.00 and a low forecast of $14.00. The average price target represents a 162.07% upside from the last price of $7.25.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Chimerix. This rating has held steady since March 2020, when it changed from a Hold consensus rating.
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.